Home | Find A Doctor | Contact Us

 

GOG-0263: RANDOMIZED PHASE III CLINICAL TRIAL OF ADJUVANT RADIATION VERSUS CHEMORADIATION IN INTERMEDIATE RISK, STAGE I/IIA CERVICAL CANCER TREATED WITH INITIAL RADICAL HYSTERECTOMY AND PELVIC LYMPHADENECTOMY.


Principal Investigator: Manjeet Chadha, MD
Time frame of study: Ongoing
Location of Study:

Mount Sinai Beth Israel
St.Luke's-Mount Sinai Roosevelt

Contact:

Continuum Cancer Research Program
(212) 844-6286

 

Summary:
Cervical cancer is classified as low, intermediate, and high risk based on the likelihood that the disease will worsen. Women with early cervical cancer with the most likely recurrence of cancer, or “high risk,” are treated with radiation and chemotherapy.  Patients with “intermediate risk” are treated with radiation alone. To reduce the risk of disease returning, subjects may have preventative external radiation therapy. The purpose of this study is to determine if weekly chemotherapy with cisplatin (a chemotherapy agent) and simultaneous radiation therapy increases the time you live disease-free compared to radiation therapy alone. You will get either standard treatment with radiation therapy OR standard treatment with radiation therapy with the addition of cisplatin chemotherapy.  


Eligibility:

  • Pathologically proven primary cervical cancer I-IIA with squamous cell carcinoma, adenosquamous carcinoma or adenocarcinoma initially treated with a standard radical hysterectomy with pelvic lymphadenectomy.
  • No other tumor at a non-uterine site
  • No previous invasive malignancies

Please call for more information

 

 

Privacy Policy | Site Map
Copyright ©  Icahn School of Medicine at Mount Sinai | Mount Sinai Health System